Taylor & Francis announce iOpenAccess - giving authors the choice 

Taylor & Francis are today delighted to announce the introduction of an
"iOpenAccess" option for authors publishing in 175 journals from T&F's
Chemistry, Mathematics and Physics portfolios, one behavioural science
journal from Psychology Press, and medical and bioscience journals from
Informa Healthcare.

From October 2006, all authors whose manuscripts are accepted for
publication in one of the iOpenAccess journals will have the option to
make their articles freely available to all via the Journal's website
for a one-off fee of $3100. 

Commenting on the launch of the initiative, Journals Publishing
Director, Dr David Green, stated: "Taylor & Francis has a strong
tradition of meeting the needs of the academic and scientific research
communities over more than two centuries. We are introducing
"iOpenAccess" only after the widest possible consultation with the
editor, author and funder communities. We are doing so in a manner which
will continue to guarantee the integrity of peer review and the rights
of authors, and which will ensure the continuing viability and quality
of major international journals with whose publishing stewardship we are
entrusted."

Mark Walport, Director of the Wellcome Trust, commented: "I am very
pleased that Taylor and Francis are now offering an open access choice
to publish in their journals. We all want to maximise the impact of
biomedical research. Ensuring the widest distribution of the results of
biomedical research is a key part of achieving that aim."

* Authors will be asked to grant a publishing licence or assign
copyright in the normal way. Selection of the "iOpenAccess" option and
payment of the appropriate fee will then allow the article to be made
available to all under a Creative Commons Licence
(Attribution-Non-commercial-No Derivatives version 2.5 ) . Under this
licence we will allow tagging and cross-referencing of articles within
repositories so that they relate back to the original research grants
and programmes. 

* Authors selecting the "iOpenAccess" option will have no embargo
restriction on posting their version of the published article to any
institutional or subject repository. Where appropriate, we will
facilitate deposit on behalf of authors into PubMedCentral. 

* We undertake to review the subscription prices of each journal with
respect to the uptake of the iOpenAccess initiative, and the relevant
information will be published on each journal's home page at
www.tandf.co.uk/journals <outbind://125/www.tandf.co.uk/journals>  

Our commitment to stringent, independent, expert peer review remains:
only accepted articles are eligible for the scheme, and authors will
only be offered the open access option when they are sent their proofs
for review. This complete separation of payment from the peer review and
acceptance process will ensure that editorial independence and quality
are not compromised. 

This initiative is a pilot 'hybrid' open access scheme in selected
subjects, and comes after the experience of a number of years'
experimentation with access schemes operated by various T&F journals, as
well as wide consultation with our editors, society partners and
research funders. We intend to increase the number of iOpenAccess
journals over the coming months, and fees may vary as we expand this
initiative into other subject areas 

Taylor & Francis has a justified reputation as a leading publisher and
trusted partner of learned societies for over 200 years. Through a
combination of organic growth and acquisitions it has become one of the
world's leading imprints for academic books and journals. The name
Taylor & Francis has long been associated with a pre-eminent tradition
of scholarly science publishing. 

 

Taylor & Francis Group
www.informaworld.com 

www.tandf.co.uk/journals <outbind://125/www.tandf.co.uk/journals> 

--------------------------------------------------------------------------------------------------------------------------------------------
The information contained in this email message may be confidential. If you are not the intended recipient, any use, interference with, disclosure or copying of this material is unauthorised and prohibited. Although this message and any attachments are believed to be free of viruses, no responsibility is accepted by Informa for any loss or damage arising in any way from receipt or use thereof.  Messages to and from the company are monitored for operational reasons and in accordance with lawful business practices. 
If you have received this message in error, please notify us by return and delete the message and any attachments.  Further enquiries/returns can be sent to [log in to unmask]